TY - JOUR T1 - Dominant negative effects of <em>SCN5A</em> missense variants JF - bioRxiv DO - 10.1101/2021.09.22.461398 SP - 2021.09.22.461398 AU - Matthew J. O’Neill AU - Ayesha Muhammad AU - Bian Li AU - Yuko Wada AU - Lynn Hall AU - Joseph F. Solus AU - Laura Short AU - Dan M. Roden AU - Andrew M. Glazer Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/09/24/2021.09.22.461398.abstract N2 - Introduction Up to 30% of patients with Brugada Syndrome (BrS) carry loss-of-function (LoF) variants in the cardiac sodium channel gene SCN5A. Recent studies have suggested that the SCN5A protein product NaV1.5 can form dimers and exert dominant negative effects.Methods We identified 35 LoF variants (&lt;10% peak current compared to wild type (WT)) and 15 partial LoF variants (10-50% peak current compared to WT) that we assessed for dominant negative behavior. SCN5A variants were studied in HEK293T cells alone or in heterozygous co-expression with WT SCN5A using automated patch clamp. To assess clinical risk, we compared the prevalence of dominant negative vs. putative haploinsufficient (frameshift/splice site) variants in a BrS case consortium and the gnomAD population database.Results In heterozygous expression with WT, 32/35 LoF variants and 6/15 partial LoF showed reduction to &lt;75% of WT-alone peak INa, demonstrating a dominant negative effect. Carriers of dominant negative LoF missense variants had an enriched disease burden compared to putative haploinsufficient variant carriers (2.7-fold enrichment in BrS cases, p=0.019).Conclusions Most SCN5A missense LoF variants exert a dominant negative effect. Cohort analyses reveal that this class of variant confers an especially high burden of BrS.Competing Interest StatementThe authors have declared no competing interest. ER -